Nu Skin
This article was originally published in The Rose Sheet
Executive Summary
Weaker than expected results in the U.S., mainland China and Japan in the third quarter have prompted the company to lower revenue expectations, projecting sales will be up 2% to $290 mil., versus earlier estimates of $298 mil.-$303 mil., Nu Skin reports Oct. 4. Earnings per share during the quarter will be in the range of $.24-$.26, compared to earlier projections of $.29-$.30. Based on Q3 expectations, Nu Skin is revising its fourth quarter revenue guidance to $300 mil.-$306 mil., "assuming an exchange rate of 112 yen to the dollar, which would result in annual revenue increasing 5% to approximately $1.2 bil. for 2005," firm adds...
You may also be interested in...
Nu Skin
Business "simplification" initiative in 2006 intended to benefit direct-seller's sales force will result in $15 mil.-$25 mil. in restructuring charges to be taken within the next few quarters, Nu Skin announces Nov. 30. As part of its strategy, company plans to "eliminate organizational redundancies, revamp administrative support functions, prioritize investments to favor profitable initiatives and markets, and increase efficiencies in our supply chain process." In addition to revenue shortfall, charges also will cause negative impact on earnings per share, firm notes. Strength of U.S. dollar against other currencies also has led company to revise fourth quarter sales estimates to $285 mil.-$290 mil. versus prior expectations of $300 mil.-$305 mil. (1"The Rose Sheet" Oct. 10, 2005, In Brief). Decline in revenue is anticipated to reduce earnings per share in Q4 by about $.03, firm adds...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.